sarcoma research laboratory university of texas, md anderson cancer center radiation-associated and...
Post on 24-Dec-2015
221 Views
Preview:
TRANSCRIPT
Sarcoma Research LaboratoryUniversity of Texas, MD Anderson Cancer Center
Radiation-associated and sporadic UPS/MFH: Searching
for novel therapeutic strategies
Keila Enitt Torres
UPS/MFH
Pleomorphic malignant fibrous histiocytoma (MFH) unclassified pleomorphic sarcoma
Current technology ? definable line of differentiation
UPS
Peak incidence in the 6th and 7th decades of life
Typically large, deep, aggressive tumors 5% - metastases at presentation (lung) <3% radiation-associated
UPS Treatment
Radical excision with negative margins Neo-Adjuvant RT is offered widely negative
margins is not possible. Chemotherapy Unresectable
disease/metastatic disease
5-year disease-specific survival 44- 66%*
Approach
Low throughput: PI3K/AKT signaling pathway Determine if AKT/mTOR axis is a relevant target
for UPS therapy High throughput: genomic/proteomic analysis
Understand genetic and molecular de-regulations UPS progression
PI3K/AKT pathway
Nature Medicine 13, 748 - 753 (2007)
HGF p-c-Met p-MEK p-AKTc-Met
Goal #1 Confirm whether the AKT/mTOR axis is a potential
target for UPS/MFH therapy Determine whether this pathway is differentially
activated in radiation-associated versus sporadic UPS
Radiation-associated sarcoma Diagnosis of RAS based on the criteria
published by Cahan, et al. in 1948.* Previous radiation tx for different tumor Development of the sarcoma - radiation field Histologically different from the primary cancer Minimum latent period of 5 years between the
radiation and development of the sarcoma Arlen et al. 1971- modified definition
Latency period of 3 years
*Cahan et al. Cancer 1948;1:3-29.
Bioresources in the laboratory
Cell lines Animal models Human Tissue
Frozen FFPE
Cell strain/cell line bank
> 60 human tumors
13 Sporadic UPS cell strains
6 Radiation-associated
UPS cell strains
RIS-819.1 RIS-023
UPS-060UPS-485 UPS-186
UPS-060
AKT/mTOR pathway is activated in UPS
UPS-186
RIS-D
L620
RIS-D
L618
hMSC
p4EBP1
pAKT
4EBP1
AKT
S6K
b-actin
UPS-060
UPS-356
UPS-DL5
11
RIS-0
23
RIS-8
19
Radiation-associated Sporadic
pS6K
Rapamycin
0 10 100
0 10 100
0 10 100
RIS -819RIS -023 UPS-485UPS-060
Radiation-associated Sporadic
0 10 100
p4EBP1
pAKT
4EBP1
AKT
S6K
b-actin
pS6K
Rapamycin
Control 0.05uM 0.1 uM 0.5 uM 1 uM 5 uM0.0
20.040.060.080.0
100.0120.0140.0
RIS-819
% C
ell P
rolif
erati
on
Con 0. 0. 0.
1 uM
5 uM
0.020.040.060.080.0
100.0120.0140.0
RIS-023
%Ce
ll Pr
olife
ratio
n
Concentration (mM)
0 0.05 0.1 0.5 1 5
0 0.05 0.1 0.5 1 5
Radi
ation
-ass
ocia
ted
Concentration (mM)
0 0.05 0.1 0.5 1 50.0
50.0
100.0
150.0UPS-060
% C
ell P
rolif
erati
on
0 0.05 0.1 0.5 1 50.0
50.0
100.0
150.0UPS-485
% C
ell P
rolif
erati
on
Spor
adic
Concentration (mM)
Concentration (mM)
pAKT
AKT
pS6K
S6K-b actin
p4EBP14EBP1
mM/4hr 0 0.05 0.1
0 0.05 0.1
UPS-060 RIS-819
PI103
PI103
0 0.05 0.1 0.5 10
20
40
60
80
100
120
RIS-819
% C
ell p
rolif
erati
on
0 0.05 0.1 0.5 10
20
40
60
80
100
120
UPS-485
% C
ell p
rolif
erati
on
0 0.05 0.1 0.5 10
20
40
60
80
100
120
UPS-060
% C
ell p
rolif
erati
on
Concentration (mM)
Radi
ation
-ass
ocia
ted
Concentration (mM)
Spor
adic
Concentration (mM)
Concentration (mM)
0 0.05 0.1 0.5 1 50
20
40
60
80
100
120
RIS-023%
Cel
l pro
lifer
ation
Control PI1030
1020304050607080
G1SG2/M
Control PI1030
102030405060708090
G1SG2/M
RIS-819
Control PI103
UPS-060
Control PI103
Cell Cycle
Migration
Control PI103
RIS-
819
Control PI1030
20
40
60
80
100
120
% M
igra
tion
UPS
-060
Control PI1030
20
40
60
80
100
120
% M
igra
tion
Invasion
Control PI103
UPS
-060
Control PI1030
20
40
60
80
100
120
% In
vasi
on
RIS-
819
Control PI1030
20
40
60
80
100
120
% In
vasi
on
In vivo studies Orthotopic Xenograft Model
1-2mm pieces of tumor
0 4 8 12 16 200
100200300400500600700800900
1000ControlPI 50 mg/mL
Days
Tum
or V
olum
e (m
m3)
*
Control PI1030
0.20.40.60.8
11.21.41.61.8
2
Tum
or w
eigh
t (g)
*
RIS-819 tumor growth
pAKT p4EBP1 pS6RP Ki67H&E
PI10
3Co
ntro
lRIS-819 Immunohistochemistry
1 4 8 12 16 24 32 40 480
50
100
150
200
250
300
350
Control
PI103 (50 mg/Kg)
Days
Tum
or V
olum
e (m
m3)
UPS-060.1 tumor growth
PI103Control
*
pAKT p4EBP1 pS6RP Ki67H&E
PI10
3Co
ntro
lUPS-060.1 Immunohistochemistry
Summary
PI3K/AKT pathway is activated in radiation-associated and sporadic UPS
RA-UPS and sporadic UPS are sensitive to PI103
Effects in vivo model => Cell death
Current studies
ProteomicsmiRNA/
non-coding RNAs
mRNAMethylation
DNA copy number variation
DNA Sequencing
Sequenome
Exon Sequencing
Array-comparative
genomic hybridization
miRNA analysis
RPPA
TMA
Reverse-phase protein lysate array for cell signaling analysis
EIF4E
29 molecules differentially
expressed
HER-2 SignalingERK/MAPK
PI3K/AKT/mTORErbB AMPK
HGF signalingIL-15 Signaling -3.5058 5.1031
(Log 2)
Mesenchymal cells
UPS
>50%P value <0.01
Unsupervised hierarchical clustering
Unsupervised hierarchical clusteringRA-UPS versus sporadic UPS
-3.5058 5.1031
(Log 2)
RA-UPS
Sporadic-UPS
Sarcoma Research LaboratoryUniversity of Texas, MD Anderson Cancer Center
Dina Lev Raphael E. Pollock Billy Wang Alexander J. Lazar Vinod Ravi
SARC (Sarcoma Alliance for Research through Collaboration)
Acknowledgments
top related